Mother-Daughter Pair Achieves 163 lb Loss via Endoscopic Sleeve Gastroplasty
Anecdotal success story of ESG in a mother-daughter pair underscores a minimally invasive option for BMI 30-50 patients. Evidence is limited to case reports without controls or long-term follow-up. Larger interventional trials are needed to confirm sustained efficacy and insurance accessibility.
Related patterns include rising ESG uptake among patients intolerant to GLP-1s, with studies noting lower discontinuation rates than pharmacotherapy alone. Gaps remain in understanding durability when comorbidities are absent and in diverse populations. Next steps require prospective registries tracking 5-year outcomes and cost-effectiveness versus medications.
ESG Registry: US annual ESG volume will surpass 8,000 cases by end of 2027 if Medicare expands coverage to BMI 30-35 without comorbidities.
Sources (3)
- [1]Healthline Mother-Daughter ESG Story(https://www.healthline.com/health-news/mother-daughter-noninvasive-weight-loss-procedure)
- [2]ESG Outcomes Meta-Analysis in Clinical Gastroenterology and Hepatology(https://www.cghjournal.org/article/S1542-3565(22)00456-8/fulltext)
- [3]Comparative Review of Endoscopic vs Pharmacologic Weight Loss in Obesity(https://jamanetwork.com/journals/jama/article-abstract/2801234)